Current Approaches Against Alzheimer's Disease in Clinical Trials

Journal of the Brazilian Chemical Society

Maresova, Petra¹  Ramalho, Teodorico C.¹  Korabecny, Jan¹  Concordia University, Montreal, Canada¹  Kuca, Kamil¹  National Institute of Mental Health, Klecany, Czech Republic¹  Klimova, Blanka¹  França, Tanos C. C.¹  University of Hradec Kralove, Hradec Kralove, Czech Republic¹  Honegr, Jan¹  Instituto Militar de Engenharia, Rio de Janeiro, Brazil¹  Soukup, Ondrej¹  Nepovimova, Eugenie¹  University Hospital Hradec Kralove, Hradec Kralove, Czech Republic¹  University of Defence, Hradec Kralove, Czech Republic¹  University of Ostrava, Ostrava, Czech Republic¹  Universidade Federal de Lavras, Lavras, Brazil¹ 

关键词:  Alzheimer's disease;    treatment;    tacrine;    rivastigmine;    galantamine;    donepezil;    huperzine A;    arecoline;    AC-42;    encenicline;    ABT-126;    rosiglitazone;    pioglitazone;    atorvastatin;    thalidomide;    minocycline;    semagacestat;    epigallocatechin gallate;    etazolate;    tramiprosate;    valproic acid;    tideglusib;    methylene blue;    immunotherapy;   

DOI  :  10.5935/0103-5053.20160048

学科分类：化学（综合）

来源: SciELO

【 摘 要 】

Alzheimer's disease (AD) is a progressive degenerative brain disease which causes mental and physical decline, gradually resulting in death. Currently, this disease represents one of the uppermost human issues, both from the medical and economic point of view. Interest in the discovery of a drug for AD is enormous. However, despite the long-term and worldwide effort for a more effective therapy, the only available treatment is a symptomatic use of acetylcholinesterase inhibitors (AChEIs) and memantine. New therapeutic approaches as well as those based on cholinergic or amyloid theory have not brought the desired benefits yet. Thus, the question is whether an effective drug for this progressive disease will ever be developed or whether people will have to rely only on prevention and minimize risk factors of AD.

【 授权许可】

Unknown